



Date: 23rd May, 2024

To,
National Stock Exchange of India Limited
Exchange Plaza,
Bandra Kurla Complex, Bandra (East),
Mumbai 400 051.

Subject: Audited Financial Results of Nidan Laboratories and Healthcare Limited for the year ended 31st March, 2024.

Reference: NSE Symbol - NIDAN

Madam / Sir,

This is to inform you that pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and other applicable provisions, the Board of Directors of the Company at its meeting held today have approved the Audited Financial Results and Auditors Report of the Company for the financial year ended 31st March, 2024.

In view of the above, we hereby enclose the following:

1. Audited Financial Results in respect of Nidan Laboratories and Healthcare Limited for the year ended 31st March, 2024.
2. Statutory Auditor's Report on Audited financial results of Nidan Laboratories and Healthcare Limited for the year ended 31st March, 2024.
3. A declaration with respect to Audit Report with unmodified opinion to the audited financial results.

This is for your information and records.

Yours faithfully,

For Nidan Laboratories and Healthcare Limited

Kunika Maheshwari
Company Secretary & Compliance Officer
ACS:66767





NIDAN LABORATORIES & HEALTHCARE LTD.

ERSTWHILE NIDAN LABORATORIES & HEALTHCARE PVT LTD

Date: 23rd May, 2024

To,

National Stock Exchange of India Limited

Exchange Plaza,

Bandra Kurla Complex, Bandra (East),

Mumbai 400 051.

Subject: Declaration w.r.t Audit Report with unmodified opinion on the Audited Financial results for the financial year ended 31st March, 2024.

Reference: NSE Symbol - NIDAN

Madam / Sir,

Pursuant to Regulation 33(3)(d) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Company hereby declares that M/s R. K. Chapawat & Co., Chartered Accountants, the Statutory Auditors of the Company have issued their Audit Report on the Audited Financial Results of the Company for the financial year ended 31st March, 2024 with unmodified opinion.

This is for your information and records.

For Nidan Laboratories and Healthcare Limited

Tejal Anil Jayakar

Director & CFO

DIN: 07984686



Swapnashilp, Behind Aarti Apt.
Vartak Road, Virar (West),
401303, Mumbai, India.



L33111MH2000PLC129883



19.45707, 72.81031



1800 2 333 999



+91 96576 41000



www.nidanhealthcare.co.in

Connect with us on :



Nidan Laboratories And Healthcare Limited

CIN - L33111MH2000PLC129883

Regd Office: SY No. 294/A H. No. 18, Swapnshilpa, Behind Aarti Apartment, Vartak Road, Virar (W), 401303

Tel No. +91 8975610000; E-Mail:cs@nidanhealthcare.co.in, Website: www.nidanhealthcare.co.in

Statement of Audited Financial Results for the half and year Ended as on 31st March 2024.

Rs in lakhs

	Particulars	Half Year ended (Rs in lakhs)			Year Ended	Year Ended
		31-Mar-24	30-Sep-23	31-Mar-23	31-Mar-24	31-Mar-23
		Audited	Unaudited	Audited	Audited	Audited
1	Income					
	a) Revenue from Operations	1,235.30	1,182.44	1,017.73	2,417.74	2,426.59
	b) Other Income	122.34	152.30	300.28	274.64	332.93
	Total Income (a+b)	1,357.64	1,334.74	1,318.01	2,692.38	2,759.52
2	Expenses					
	a) Cost of Materials Consumed	47.60	47.40	53.81	95.00	123.84
	b) Changes in inventories of Finished Goods, Work in Progress and Stock- in- Trade	(9.82)	16.15	(14.15)	6.33	(14.94)
	c) Employee benefit expenses	232.33	227.95	284.81	460.28	499.88
	d) Finance Costs	120.37	97.69	119.07	218.06	222.31
	e) Depreciation and Amortization expenses	159.08	127.52	166.14	286.60	309.82
	f) Other Expenses	653.86	557.85	529.35	1,211.71	1,137.45
	Total Expenses (a to f)	1,203.41	1,074.56	1,139.03	2,277.97	2,278.36
3	Profit before Exceptional and Extraordinary Items & Tax	154.23	260.18	178.98	414.41	481.16
4	Exceptional & Extraordinary Items	651.27	-	-	651.27	-
5	Profit before Tax and after exceptional & extraordinary item (3-4)	(497.04)	260.18	178.98	(236.86)	481.16
6	Tax Expenses					
	a) Current Tax	52.02	67.98	39.49	120.00	130.14
	b) Deferred Tax Asset/Liability	(35.51)	1.86	17.35	(33.65)	(2.94)
	c) Tax of earlier year	1.91	(1.90)	-	0.01	-
	Total tax expenses	18.43	67.94	56.84	86.37	127.20
7	Profit for the period / year	(515.47)	192.24	122.14	(323.23)	353.96
8	Paid-up equity share capital (Face value of Rs 10/- per share)	1,390.00	1,390.00	1,390.00	1,390.00	1,390.00
	Earnings Per Share (not annualized)					
	a) Basic EPS	-3.71	1.38	0.88	-2.33	2.55
9	b) Diluted EPS	(3.71)	1.38	0.88	(2.33)	2.55

Notes:

1) The above Financial Results are reviewed by the Audit Committee and thereafter approved and taken on record by the Board of Directors at their meeting held on 23rd May 2024.

2) The equity shares of the company are listed on SME Stock Exchange as referred in Chapter XB of SEBI (Issue of Capital and Disclosure requirements) Regulations, 2009 and hence exempted from Compulsary adoption of Ind AS for the preparation of Financial statements vide Notification dated 16th February, 2015 issued by ministry of corporate affairs.

3) Exceptional items for the half year ended 31st March 2024 reported comprise of :

(a) Provision created on Sundry debtors which were outstanding for a long period of Rs 536.17 lakhs

(b) Interior work at rented diagnostic centers which were capitalized under office building (leasehold) category have been discarded due to closure of those center having Written down value of Rs 115.10 lakhs

4) The Company does not have different segments and hence segment wise reporting is not applicable to the Company.

5) The figures of the corresponding previous half year /year have been regrouped/rearranged wherever considered necessary to make them comparable





For and on behalf of Board of Directors
Nidan Laboratories and Healthcare Limited

Tejal Amil Jayakar
Tejal Amil Jayakar
Executive Director & CFO
DIN:07984686

Date : 23rd May 2024
Place : Virar

Nidan Laboratories And Healthcare Limited
Statement of Assets & Liabilities as at 31st March 2024


		Rs in lakhs	
	Particulars	As at 31st March 2024 (Audited)	As at 31st March 2023 (Audited)
I	Equity & Liabilities		
	1. Shareholders' funds		
	Equity Share Capital	1,390.00	1,390.00
	Reserves and Surplus	5,230.61	5,553.84
		6,620.61	6,943.84
	2. Non - Current Liabilities		
	(a) Long - Term Borrowings	429.38	477.49
	(b) Other Long term liabilities	16.64	16.74
	(c) Long Term Provisions	56.47	45.24
		502.49	539.47
	3. Current Liabilities		
	(a) Short - Term Borrowings	814.08	615.50
	(b) Trade Payables		
	(i) Total outstanding due of micro enterprises and small enterprises	15.42	13.38
	enterprises and small enterprises	57.54	7.23
	(c) Other Current Liabilities	127.31	53.79
	(d) Short - Term Provisions	117.63	266.95
		1,131.98	956.85
	TOTAL	8,255.08	8,440.16
II	Assets		
	1. Non - Current Assets		
	(a) Property Plant & Equipment and Intangible Assets		
	(i) Property, Plant & Equipments	1,793.51	2,136.62
	(ii) Intangible Asset	1.71	2.64
	(ii) Capital workin progress	3.50	-
	(b) Non-Current Investments	-	-
	(c) Long - Term Loans and Advances	3,276.82	4,076.05
	(d) Deferred Tax Asset (Net)	81.95	48.30
	(e) Other Non Current Assets	69.82	88.44
		5,227.31	6,352.05
	2. Current Assets		
	(a) Inventories	30.19	36.52
	(b) Trade Receivables	52.44	602.61
	(c) Cash and Cash Equivalents	284.99	841.94
	(d) Short - Term Loans and Advances	2,396.25	336.18
	(e) Other Current Assets	263.90	270.86
		3,027.77	2,088.11
	TOTAL	8,255.08	8,440.16
		For and on behalf of Board of Directors Nidan Laboratories and Healthcare Limited  Anil Jayakar Executive Director & CFO DIN:07984686	
Date : 23rd May 2024 Place : Virar			

Nidan Laboratories And Healthcare Limited
Statement Of Cash Flows For The Year Ended 31st March, 2024

Particulars	Rs. in lakhs	
	Year ended 31st March 2024	Year ended 31st March 2023
A - CASH FLOW FROM OPERATING ACTIVITIES		
Profit Before Tax	(236.87)	481.16
Add/ (less) Adjustment for:		
Interest Income	(264.64)	(288.39)
Interest Expenses	199.17	200.09
Interest on income tax	9.38	9.39
Sundry Balance w/off	34.60	
Depreciation on property plant & equipment	286.60	309.82
Loss on discard of Property plant & Equipment	115.10	-
Provision for Doubtful debts	536.17	-
(Gain)/loss on disposal of property, plant and equipment	2.89	(26.90)
Operating Profit Before Working Capital Changes	682.40	685.17
Add/ (less): Adjustments for Changes in working capital:		
(Increase) / decrease in Trade Receivable	14.00	(66.44)
(Increase)/ decrease in Other Current Assets	(11.51)	(18.49)
(Increase) / decrease in Short Term Loans and Advances	(2,044.56)	591.83
(Increase) / decrease in Other Non current assets	2.49	(15.48)
(Increase) / decrease in Inventories	6.33	(14.94)
Increase / (decrease) in Trade payables	52.36	(94.26)
Increase / (decrease) in Long term liability	(0.10)	(17.30)
Increase / (decrease) in Other current Liability	73.51	6.71
Increase / (decrease) in Short Term Provision	1.25	(0.45)
Increase / (decrease) in Long term Provisions	11.24	43.68
Cash Generated from Operations	(1,212.61)	1,100.02
Add/ (less) : Direct taxes paid (net of refund received)	(279.98)	(3.11)
Net Cash Inflow / (outflow) from Operating Activities	(1,492.58)	1,096.91
B - CASH FLOW FROM INVESTING ACTIVITIES		
Capital work in progress	(73.63)	(66.83)
Proceeds from sale of property, plant and equipment	9.58	72.00
(Increase) / Decrease in Long term loans and advances (net)	1,032.41	(33.70)
Interest received	15.96	-
Net cash inflow/(outflow) from Investing Activities	984.32	(28.53)
C - CASH FLOW FROM FINANCING ACTIVITIES		
Proceeds / (repayment) of borrowings (net)	148.58	(836.49)
Interest Expenses	(197.26)	(200.09)
Net Cash inflow/(outflow) from Financing Activities	(48.69)	(1,036.58)
Net (Decrease) / Increase in Cash and Cash Equivalents (A+B+C)	(556.95)	31.80
Add: Cash and Cash Equivalents at the beginning of the year	841.94	810.14
Cash and Cash Equivalents at the end of the year	284.99	841.94

Cash and Cash Equivalents at the end of the year consists of cash in hand and Balances with Banks are as follows :

Particulars	Rs. in lakhs	
	As at 31st March 2024	As at 31st March 2023
Cash on hand	261.82	823.20
Balances with Banks	23.17	18.74
Cash and Cash Equivalents	284.99	841.94



For and on behalf of the Board of Directors
Nidan Laboratories And Healthcare Limited

(Signature)
Tejal Anil Jayakar
Executive Director & CFO
DIN: 07984686

Date : 23rd May 2024
Place : Virar

Nidan Laboratories And Healthcare Limited

CIN - L33111MH2000PLC129883

Regd Office: SY No. 294/A H. No. 18, Swapnshilpa, Behind Aarti Apartment,

Vartak Road, Virar (w), 401303

Tel No. +91 8975610000, E-Mail : cs@nidanhealthcare.co.in, Website : www.nidanhealthcare.co.in

Statement of Financial Results for the half and year Ended on 31st March 2024


Rs in lakhs

S.No	Particulars	Half Year Ended 31st March 2024 (Audited)	Half Year Ended 30th September 2023 (Unaudited)	Half Year Ended 31st March 2023 (Audited)	Year Ended 31st March 2024 (Audited)	Year Ended 31st March 2023 (Audited)
1	Total Income from Operations	1,235.30	1,182.44	1,017.73	2,417.74	2,426.59
2	Net Profit for the period / year (before tax, exceptional and/or extraordinary items)	154.23	260.18	178.98	414.41	481.16
3	Net Profit for the period / year before tax (after exceptional and/or extraordinary items)	(497.04)	260.18	178.98	(236.86)	481.16
4	Net Profit for the period / year after tax (after exceptional and/or extraordinary items)	(515.47)	192.24	122.14	(323.23)	353.96
5	Total Comprehensive income for the period / year [comprising Profit for the period / year (after tax) and other comprehensive Income (after tax)]	(515.47)	192.24	122.14	(323.23)	353.96
6	Paid up Equity Share Capital	1,390.00	1,390.00	1,390.00	1,390.00	1,390.00
7	Reserves (exluding revaluation reserve)	(515.48)	5,746.09	51.77	5,230.61	5,553.84
8	Earnings Per Share (of Rs 10/-each) (not annualized)					
	Basic	-3.71	1.38	0.88	-2.33	2.55
	Diluted	-3.71	1.38	0.88	-2.33	2.55

1) The above is an extract of the detailed format of Annual Financial Results filed with National Stock Exchange Limited under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Financial Results are available on the Stock Exchange websites (www.nseindia.com/) and Company's website : www.nidanhealthcare.co.in

2) The Company does not have different segments and hence segment wise reporting is not applicable to the Company.

3) Figures of the previous period / year have been regrouped wherever necessary, to correspond with the figures of the current period.



**For and on behalf of Board of Directors
Nidan Laboratories and Healthcare Limited**

(Signature)
Nejal Anil Jayakar
Executive Director & CFO
DIN:07984686

Date : 23rd May 2024
Place : Virar



R. K. CHAPAWAT & CO.

CHARTERED ACCOUNTANTS

Office : 122, Shripal Shopping Center, Near Petrol Pump, Agashi Road, Virar (West) Dist - Palghar : 401303.

Contact : +91-9323791318 / 0250-2513406, **E-mail :** ravindra_chapawat@rediffmail.com

Independent Auditor's Report on the Annual Audited Financial Results of Nidan Laboratories and HealthCare Limited for the half-year and year ended 31st March, 2024 of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation's, 2015 (As Amended)

To,
The Board of Directors of
Nidan Laboratories and HealthCare Limited

Opinion

We have audited the accompanying financial results of Nidan Laboratories and HealthCare Limited ("the Company") for the half year ended 31st March, 2024 and the year-to-date results for the period from 1st April 2023 to 31st March, 2024, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us these financial results:

- i) are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- ii) give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards and other accounting principles generally accepted in India of the net loss and other financial information for the half year ended 31st March, 2024 and the year-to-date results for the period from 1st April, 2023 to 31st March, 2024.

Basic for opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 (the Act). Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Financial Results section of our report. We are independent of the Company in accordance with the Code of ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.



R.K. CHAPAWAT & CO.

CHARTERED ACCOUNTANTS

Management's and Board of Directors Responsibilities for the Financial Results

The statement which is the responsibility of the company's management and approved by the board of directors, has been prepared on the basis of financial statement. The company's Board of Directors are responsible for the preparation of these financial results that give true and fair view of the net loss and other financial information in accordance with the Accounting Standards prescribed under section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations.

This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.,

In preparing the financial results, the Management & Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.


The Board of Directors is also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Results

Our objectives are to obtain reasonable assurance about whether the financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement



R.K. CHAPAWAT & CO.

CHARTERED ACCOUNTANTS

resulting from fraud is higher, than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override internal control.

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in due financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in the manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.



R.K. CHAPAWAT & CO.

CHARTERED ACCOUNTANTS

Other, Matters

The Statement includes the results for the half year ended 31st March, 2024 being the balancing figure between audited figures in respect of the full financial year and the unaudited years to date figures up to the Half year (30th September, 2023) of the current financial year which were subject to limited review by us. Report or the Statement is not modified in respect of this matter.

For R. K. Chapawat & Co.
Chartered Accountants
Firm Registration no. 101708W

K. Chapawat

Kamlesh Chapawat
Partner
Membership No.: 181441
Udin No.: 24181441BKGEKR5591
Date: 23rd May 2024
Place: Virar

